Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Expected to Reach $3.4 Billion by 2025 - Research and Markets

Research and Markets
Posted on: 04 Dec 17

The "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Analysis By Therapy (Chemotherapy, Hyper-CVAD, Linker Regimen, Targeted Therapy, Radiation Therapy), And Segment Forecasts, 2014 - 2025" report has been added to Research and Markets' offering.

The global acute lymphocytic/lymphoblastic leukemia therapeutics market is expected to reach USD 3.4 billion by 2025, according to a new report. Increasing public and private initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL), rising number of bone marrow biopsies, and availability of other treatment options are factors expected to increase the adoption of ALL procedures. For instance, The Baby Friendly Initiative Program by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative approach between hospitals and healthcare institutions in Canada, aim to provide free diagnosis and treatment services to infants suffering from ALL, who meet certain eligibility criteria.

Furthermore, rising incidence of ALL is anticipated to boost the market. The disease is prevalent among children below 5 years of age. The risk of contracting ALL is the highest between the ages of 0 and 20. On the other hand, adults are also at a risk of developing this condition. The median age of men diagnosed with this condition is approximately 55 years.

Companies Mentioned

  • Erytech Pharma.
  • Spectrum Pharmaceuticals Inc.
  • Genmab A/S
  • Bristol-Myers Squibb Company
  • Genzyme Corporation (Sanofi)
  • Pfizer, Inc.
  • Sigma-tau spa
  • Novartis AG
  • Celgene Corporation
  • Juno Therapeutics, Inc.

Key Topics Covered:

Chapter 1 Research Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Acute lymphocytic/lymphoblastic leukemia therapeutics market Variables, Trends & Scope

Chapter 4 Acute lymphocytic/lymphoblastic leukemia therapeutics market: Product Estimates & Trend Analysis

Chapter 5 Acute lymphocytic/ lymphoblastic leukemia therapeutics market: Type Estimates & Trend Analysis

Chapter 6 Acute lymphocytic/ lymphoblastic leukemia therapeutics market: Regional Estimates & Trend Analysis, by Product

Chapter 7 Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/research/hgqj7f/acute

View source version on businesswire.com: http://www.businesswire.com/news/home/20171204005405/en/

Business Wire
www.businesswire.com

Last updated on: 04/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.